UK-414495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414495 acts as a potent selective inhibitor of the enzyme neutral endopeptidase which normally serves to break down the neuropeptide VIP. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation.
This page contains content from the copyrighted Wikipedia article "UK-414495"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
